BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V}

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Micawber who wrote (62)	2/7/1999 9:40:00 PM
From: CPAMarty	Read Replies (1) of 423

Investors Business Daily has an interesting story on page A4 of the 2/8/99 edition on Sugen (SUGN). Seems like (to a layman anyway) they are into the many of the same areas as IMCL (cancer, angiogenesis, ok not exactly like); only SUGN's projects seem to be more diversified and behind (in terms of the level of trials) that of IMCL's. So why is SUGN trading at $17 while IMCL is under $11? Richard Van Den Broek from H & Q was quoted in the IBD article - therefore i assume H & Q follows - maybe the difference in price is better explained by analyst coverage than the science.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next